Exploring the Role of BRAF Inhibition in Primary CNS Malignancies

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss current treatment approaches in central nervous system malignancies.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the use of BRAF inhibitors in the treatment of patients with central nervous system malignanices.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the novel BRAF inhibitor plixorafenib and its ongoing evaluation in central nervous system malignancies.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the safety profile and management of toxicities associated with BRAF inhibitors in central nervous system tumors.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss available data for plixorafenib in central nervous system tumors harboring BRAF V600 mutations from the FORTE trial.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss ongoing research to watch in primary central nervous system tumors.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss potential directions for future research in primary central nervous system malignancies.